These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 25906123)

  • 41. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.
    Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P
    Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The utility of villin and mammaglobin in the differential diagnosis between intrahepatic cholangiocarcinoma and breast cancer.
    Yang Z
    Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):19-25. PubMed ID: 25153498
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases.
    Espinosa I; Gallardo A; D'Angelo E; Mozos A; Lerma E; Prat J
    Int J Gynecol Pathol; 2015 May; 34(3):257-65. PubMed ID: 25844549
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
    Ciampa A; Fanger G; Khan A; Rock KL; Xu B
    Cancer; 2004 Dec; 102(6):368-72. PubMed ID: 15558786
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Utility of GATA3, mammaglobin, GCDFP-15, and ER in the detection of intrathoracic metastatic breast carcinoma.
    Dyhdalo KS; Booth CN; Brainard JA; Croyle MC; Kolosiwsky AM; Goyal A; Gildea TR; Almeida FA; Nassar A; Reynolds JP
    J Am Soc Cytopathol; 2015; 4(4):218-224. PubMed ID: 31051757
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GATA-binding protein 3, gross cystic disease fluid protein-15 and mammaglobin have distinct prognostic implications in different invasive breast carcinoma subgroups.
    Ni YB; Tsang JY; Chan SK; Tse GM
    Histopathology; 2015 Jul; 67(1):96-105. PubMed ID: 25425335
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma.
    Han JH; Kang Y; Shin HC; Kim HS; Kang YM; Kim YB; Oh SY
    Arch Pathol Lab Med; 2003 Oct; 127(10):1330-4. PubMed ID: 14521461
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas.
    Liu H; Shi J; Wilkerson ML; Lin F
    Am J Clin Pathol; 2012 Jul; 138(1):57-64. PubMed ID: 22706858
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes.
    Wang X; Tsang JYS; Lee MA; Ni YB; Tong JH; Chan SK; Cheung SY; To KF; Tse GM
    Cancer Res Treat; 2019 Apr; 51(2):706-717. PubMed ID: 30134648
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas.
    Zhao L; Antic T; Witten D; Paner GP; Taxy JB; Husain A; Gwin K; Mirza MK; Lingen MW; Tretiakova MS
    Am J Surg Pathol; 2013 Dec; 37(12):1876-81. PubMed ID: 24121175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer.
    Huo L; Zhang J; Gilcrease MZ; Gong Y; Wu Y; Zhang H; Resetkova E; Hunt KK; Deavers MT
    Histopathology; 2013 Jan; 62(2):267-74. PubMed ID: 22963676
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The diagnostic utility of trichorhinophalangeal syndrome type 1 immunohistochemistry for metastatic breast carcinoma in effusion cytology specimens.
    Chen CJ; Hang JF; Chen YA; Lin SJ; Chiu HM; Hsu CY; Lai CR; Yang CS
    Cancer Cytopathol; 2023 Apr; 131(4):226-233. PubMed ID: 36399408
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preferential expression of NY-BR-1 and GATA-3 in male breast cancer.
    Biserni GB; Di Oto E; Moskovszky LE; Foschini MP; Varga Z
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):199-204. PubMed ID: 29116378
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of the effectiveness of GATA3 as a prognostic factor in breast cancer.
    Fararjeh AS; Tu SH; Chen LC; Liu YR; Lin YK; Chang HL; Chang HW; Wu CH; Hwang-Verslues WW; Ho YS
    Hum Pathol; 2018 Oct; 80():219-230. PubMed ID: 29902578
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bone marrow mammaglobin-1 (SCGB2A2) immunohistochemistry expression as a breast cancer specific marker for early detection of bone marrow micrometastases.
    Talaat IM; Hachim MY; Hachim IY; Ibrahim RAE; Ahmed MAER; Tayel HY
    Sci Rep; 2020 Aug; 10(1):13061. PubMed ID: 32747636
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnostic utility and sensitivities of matrix Gla protein (MGP), TRPS1 and GATA3 in breast cancer: focusing on metastatic breast cancer, invasive breast carcinoma with special features, and salivary gland-type tumours.
    Wu Y; Chen F; Pan L; Chao X; Li M; Luo R; Chen K; Zheng C; Du T; He J; Sun P
    Pathology; 2024 Jun; 56(4):516-527. PubMed ID: 38570266
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study.
    El Hag MI; Ha J; Farag R; El Hag AM; Michael CW
    Diagn Cytopathol; 2016 Sep; 44(9):731-6. PubMed ID: 27338760
    [TBL] [Abstract][Full Text] [Related]  

  • 58. GATA3 expression in advanced breast cancer: prognostic value and organ-specific relapse.
    McCleskey BC; Penedo TL; Zhang K; Hameed O; Siegal GP; Wei S
    Am J Clin Pathol; 2015 Nov; 144(5):756-63. PubMed ID: 26486740
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnostic utility of the combined use of HNF4A and GATA3 in distinction between primary and metastatic breast and gastric carcinomas.
    Saad DZ; Sidhom KF; Gadallah MF; Samir NA; Shakweer MM
    APMIS; 2021 Sep; 129(9):548-555. PubMed ID: 34120367
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity.
    Bhargava R; Beriwal S; Dabbs DJ
    Am J Clin Pathol; 2007 Jan; 127(1):103-13. PubMed ID: 17145637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.